Maxim raised the firm’s price target on Kazia Therapeutics (KZIA) to $20 from $15 and keeps a Buy rating on the shares. The company has made significant progress in developing paxalisib for triple-negative breast cancer and has read out consistently positive data across both TNBC and ER+/HER2-breast cancer, and while it’s early stage, the data thus far appears promising, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics’ paxalisib combination shows tumor reduction
- Kazia Therapeutics files to sell 232,956 American Depositary Shares for holders
- Two new option listings and nine option delistings on September 22nd
- Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments in Cancer Treatment
- Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib